Atherogenic dyslipidaemia - One of the components of the metabolic syndrome;Aterogénna dyslipidémia - Súčast́' metabolického syndrómu

Kardiologia

Volumn 14, Issue 3, 2005, Pages 124-130

  Fábryová, L'ubomíra ^a  

^a Fakultnej NsP Milosrdní Bratia ^*  (Slovakia)

Author keywords

Apolipoprotein C III; Atherogenic lipoprotein phenotype; Metabolic syndrome; Phenotype of hypertriglyceridemic waist; Triglyceride HDL cholesterol ratio

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; CARBOHYDRATE DIET; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DYSLIPIDEMIA; HIGH RISK POPULATION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; LIVER METABOLISM; LOW FAT DIET; METABOLIC SYNDROME X; OBESITY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 18144420854     PISSN: 12100048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Crepaldi G, Tinego A, Avogaro A. The metabolic syndrome: diabetes, obesity, hyperlipidemia and hypertension. Amsterdam: Elsevier 2003:304.
2. Executive summary of the third report of the NCEP expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001;285:2486-2497.
3. Rašlová K, Filipová S, Mike š Z, et al. Odporúčania pre optimálnu diagnostiku a liečbu dyslipoproteinémií u dospelých - Lipidový konsenzus 2. Interná medicina 2003;1:10-18.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
5. European Group for the Study of Insulin Resistance (EGIR): Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabete Metab 2002;28:364-376.
6. Grundy SM, Hansen B, Smith SC, et al. Clinical management of the metabolic syndrome. Circulation 2004;109:551-556.
7. Krauss RM. Atherogenic lipoproteins in the metabolic syndrome. MetS insight 2004;4:13-17.
8. Ginsberg HN. New perspectives on atherogenesis: Role of abnormal trigylceride-rich lipoprotein metabolism. Circulation 2002;106:2137-2142.
9. Fábryová L. Manažment kardiovaskulárneho rizika u pacientov s metabolickým syndrómom. Int Med 2004; 4:35-42.
10. Lee SJ, Campos H, Moye LA, et al. LDL containing apolipoprotein C- III is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003;23:853-858.
11. Alaupovic P, Mack WJ, Knight-Gibson, C et al. The role of triglyceride-rich lipoprotein families in the progression of atheroslcerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol. 1997;17:715-722.
12. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-2838.
13. Assman G, Schulte H, von Eckardstein A, et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(Suppl):S11-20.
14. Austin MA, Breslow JL, Hennekens Ch, et al. Low-density lipoprotein subclass patterns and the risk of myocardial infarction. JAMA 1998;260:1917-1921.
15. Miller M. Epidemiology of triglyceride as coronary artery disease risk factor. Clin Cardiol 1999;22(Supll. 2):11-16.
16. Stavenow L, Kjellström T. Influence of serum triglyceride levels on the risk for myocardial infarction in 12510 middle aged males: interaction with serum cholesterol. Atherosclerosis 1999;147:243-247.
17. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol levels: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219.
18. Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins Ann Rev Med 2003;54:321-341.
19. Gordon DJ, Probstfield JL, Garrison RJ, et al. HDL-cholesterol and cardiovascular disease. Four prospective American Studies. Circulation 1989;79:8-15.
20. Sacks FM for the experts group on HDL cholesterol. The role of high density lipoprotein cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations. Am J Cardiol 2002;90:139-143.
21. Fábryová L'. Nové milénium - nové stratégie v prevencii a liečbe ischemickej choroby srdca. HDL-cholesterol ako nový terapeutický ciel'. Cardiol 2002; 5:307-316.
22. Lamarche B, Despres JP, Moorjani S, et al. Prevalence of dyslipidemia phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol 1995;75:1189-1195.
23. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA 1993;269:3002-3008.
24. Gotto AM, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease. A working group report and update. J Am Coll Cardiol 2004;43:717-724.
25. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1998;206:641-651.
26. Robins SJ. Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-Density Lipoprotein Intervention Trial Diabetes. Am J Cardiol 2001;88(Suppl):19N-23N.
27. Ericsson CG, Hamsten A, Nillson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.
28. Syvanne M, Nieminen MS, Frick MH, et al. for the Lopid Coronary Angiography Trial /LOCAT/ Study group. Association between lipoproteins and the progression of coronary and vein graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation 1998;98:1993-1999.
29. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-910.
30. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Study. Circulation 1998;97:1453-1460.
31. Sacks FM, Tonkin AM, Shepherd J, et al. for the Prospective Pravastatin Pooling Project Investigators Group: Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-1900.
32. Gotto AM, Whitney E, Stein EA, et al. Relation between lipid levels and on treatment parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study. Circulation 2000;101:477-484.
33. Simes RJ, Marschenr JC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial. Circulation 2002;105:1162-1169.
34. Nissen SE, Tsunoda T, Tuycu EM, et al. Effect of recombinant Apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA 2003;290:2292-2300.
35. Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733-1777.
36. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002;90:89-94.
37. Miller BD, Alderman EL, Haskell WL, et al. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996;94:2146-2153.
38. Zambon A, Hokansom JE, Brown BG, et al. Evidence for a next pathophysiological mechanism for coronary artery disease regression: hepatic lipase mediated changes in LDL density. Circulation 1999;99:1959-1964.
39. Lemieux I, Pascot A, Couillard Ch, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad in men. Circulation 2000;102:179-184.
40. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up □ in the Copenhagen Male Study. Circulation 1998;97:1029-1036.
41. Gaziano JM, Hennekens CH, ODonnell CJ, et al. Fasting triglycerides, high-density lipoprotein and risk of myocardial infarction. Circulation 1997;96:2520-2525.
42. Boizel R, Benhamou PY, Lardy B, et al. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care 2000;23:1679-1685.
43. Jeppesen J, Hein HO, Suadicani P, et al. Low triglycerides - high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001;161:361-366.
44. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:817-823.
45. Hanak V, Munoz J, Teague J, et al. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. Am J Cardiol 2004;94:219-222.